abstract |
The present invention relates to a cancer cell-specific complex for targeting cancer. A complex for targeting cancer, according to the present invention, comprises EGF, but is affected more by lysosome activity than by an EGFR signaling pathway, and thus can overcome the shortcomings of EGF treatment-based diagnostic and therapeutic compositions and provide successfully personalized and improved effects of cancer treatment, prevention, and alleviation. A diagnostic composition according to the present invention enables the prediction of anticancer efficiency, of a therapeutic composition of the present invention, in a subject, and thus enables anticancer treatment to be stably designed. |